|Past two years||Past Year||Past 30 Days|
|Full Text Views||2||0||0|
From the study of 296 cases of Bancroftian filariasis treated with Hetrazan in British Guiana the following conclusions and recommendations for treatment seem to be justified:
The explanation of systemic reactions which sometimes occur during the treatment of this infection with Hetrazan on an allergic basis is further strengthened by the following facts:
Despite the fact that symptoms during treatment have never reached alarming proportions, the possibility of severe allergic reactions should not be overlooked. It would probably be well to start treatment with low doses (0.2 to 0.5 mg. per kg.) in hypersensitized individuals with a history of unusually severe filarial attacks, although, as shown in the Kwakwani group, systemic reactions may occur during treatment with this dosage range. The possibility of alleviating the severity of some reactions by the use of anti-allergic medication should be considered.
Former resident physician, Berbice Company Ltd., American Cyanamid Company, Kwakwani, British Guiana. Present address: 336 West End Avenue, New York, New York.
Parasitologist, Research Division, Lederle Laboratories Division, American Cyanamid Company, Pearl River, New York.